US2014178441A1PendingUtilityA1

Pharmaceutical formulation for reducing frequency of urination and method of use thereof

68
Assignee: WELLESLEY PHARMACEUTICALS LLCPriority: Jul 8, 2010Filed: Mar 4, 2014Published: Jun 26, 2014
Est. expiryJul 8, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:David A. Dill
A61K 31/616A61K 31/122A61K 9/2866A61K 9/2846A61K 9/284A61K 9/08A61K 9/0019A61K 31/437A61K 45/06A61K 31/167A61K 31/12A61K 31/405A61K 31/192A61K 31/216A61K 31/4985
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for reducing frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A pharmaceutical composition, comprising:
 one or more analgesic agents;   an inhibitor of phosphodiesterase type 5 (PDE 5 inhibitor); and   a pharmaceutically acceptable carrier.   
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein said one or more analgesic agents are formulated for extended-release and wherein said PDE 5 inhibitor is formulated for immediate-release. 
     
     
         17 . The pharmaceutical composition of  claim 15 , wherein said one or more analgesic agents are formulated for delayed-release and wherein said PDE 5 inhibitor is formulated for immediate-release. 
     
     
         18 . The pharmaceutical composition of  claim 15 , wherein said one or more analgesic agents and said PDE 5 inhibitor are formulated for extended release over a period of 2-12 hours. 
     
     
         19 . The pharmaceutical composition of  claim 15 , wherein said PDE 5 inhibitor and 20-60% of each of said one or more analgesic agents are formulated for immediate release, and wherein remainder of each of said one or more analgesic agents is formulated for extended release. 
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein said pharmaceutical composition is further coated with an enteric coating. 
     
     
         21 . The pharmaceutical composition of  claim 15 , wherein said composition is formulated for immediate release. 
     
     
         22 . The pharmaceutical composition of  claim 15 , wherein said composition is formulated for delayed release. 
     
     
         23 . The pharmaceutical composition of  claim 15 , wherein said composition is formulated for extended release. 
     
     
         24 . The pharmaceutical composition of  claim 15 , wherein said composition is formulated for delayed-extended release. 
     
     
         25 . The pharmaceutical composition of  claim 15 , wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said one or more analgesic agents are present in an amount of 1-2000 mg per agent. 
     
     
         26 . The pharmaceutical composition of  claim 15 , wherein said one or more analgesic agents comprises acetaminophen. 
     
     
         27 . The pharmaceutical composition of  claim 26 , wherein said acetaminophen is present in an amount of 1-2000 mg. 
     
     
         28 . The pharmaceutical composition of  claim 26 , wherein said acetaminophen is present in an amount of 30-300 mg. 
     
     
         29 . The pharmaceutical composition of  claim 26 , wherein said acetaminophen is present in an amount of 300-1000 mg. 
     
     
         30 . The pharmaceutical composition of  claim 26 , wherein said acetaminophen is present in an amount of 1000-2000 mg. 
     
     
         31 . The pharmaceutical composition of  claim 15 , wherein said PDE 5 inhibitor is tadalafil. 
     
     
         32 . The pharmaceutical composition of  claim 15 , further comprising an additional agent selected from the group consisting of antimuscarinic agents, antidiuretics, spasmolytics and zolpidem. 
     
     
         33 . The pharmaceutical composition of  claim 32 , wherein said additional agent is an antimuscarinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin, fesoterodine, tolterodine, trospium, atropine, and tricyclic antidepressants. 
     
     
         34 . The pharmaceutical composition of  claim 32 , wherein said additional agent is an antidiuretic selected from the group consisting of antidiuretic hormone (ADH), angiotensin II, aldosterone, vasopressin, vasopressin analogs, vasopressin receptor agonists, atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) receptor antagonists, and somatostatin type 2 receptor antagonists. 
     
     
         35 . The pharmaceutical composition of  claim 32 , wherein said additional agent is a spasmolytic selected from the group consisting of carisoprodol, benzodiazepines, baclofen, cyclobenzaprine, metaxalone, methocarbamol, clonidine, clonidine analogs and dantrolene. 
     
     
         36 . The pharmaceutical composition of  claim 32 , wherein said additional agent is zolpidem. 
     
     
         37 . The pharmaceutical composition of  claim 15 , wherein said pharmaceutical composition is coated with an enteric coating.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.